![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HOMER2 |
Gene summary for HOMER2 |
![]() |
Gene information | Species | Human | Gene symbol | HOMER2 | Gene ID | 9455 |
Gene name | homer scaffold protein 2 | |
Gene Alias | ACPD | |
Cytomap | 15q25.2 | |
Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | Q9NSB8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9455 | HOMER2 | Pt13.b | Human | Liver | HCC | 1.23e-10 | -5.05e-01 | 0.0251 |
9455 | HOMER2 | Pt13.c | Human | Liver | HCC | 2.99e-10 | -6.21e-01 | 0.0076 |
9455 | HOMER2 | Pt14.d | Human | Liver | HCC | 1.10e-13 | -5.42e-01 | 0.0143 |
9455 | HOMER2 | S028 | Human | Liver | HCC | 4.56e-04 | -3.04e-01 | 0.2503 |
9455 | HOMER2 | PTCwithHT_8 | Human | Thyroid | HT | 1.09e-02 | -1.19e-01 | 0.0351 |
9455 | HOMER2 | male-WTA | Human | Thyroid | PTC | 1.20e-26 | 2.27e-01 | 0.1037 |
9455 | HOMER2 | PTC01 | Human | Thyroid | PTC | 5.17e-06 | 4.83e-02 | 0.1899 |
9455 | HOMER2 | PTC03 | Human | Thyroid | PTC | 3.88e-03 | 2.06e-01 | 0.1784 |
9455 | HOMER2 | PTC04 | Human | Thyroid | PTC | 2.11e-13 | 2.50e-01 | 0.1927 |
9455 | HOMER2 | PTC05 | Human | Thyroid | PTC | 1.68e-14 | 6.65e-01 | 0.2065 |
9455 | HOMER2 | PTC06 | Human | Thyroid | PTC | 2.13e-19 | 4.90e-01 | 0.2057 |
9455 | HOMER2 | PTC07 | Human | Thyroid | PTC | 1.13e-20 | 2.76e-01 | 0.2044 |
9455 | HOMER2 | ATC09 | Human | Thyroid | ATC | 4.29e-07 | 2.12e-01 | 0.2871 |
9455 | HOMER2 | ATC12 | Human | Thyroid | ATC | 3.84e-02 | -1.01e-01 | 0.34 |
9455 | HOMER2 | ATC13 | Human | Thyroid | ATC | 5.07e-05 | -5.65e-02 | 0.34 |
9455 | HOMER2 | ATC1 | Human | Thyroid | ATC | 8.01e-06 | 3.05e-01 | 0.2878 |
9455 | HOMER2 | ATC5 | Human | Thyroid | ATC | 2.04e-03 | -5.10e-02 | 0.34 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000189410 | Endometrium | AEH | tissue homeostasis | 50/2100 | 268/18723 | 2.04e-04 | 2.54e-03 | 50 |
GO:00602499 | Endometrium | AEH | anatomical structure homeostasis | 55/2100 | 314/18723 | 5.27e-04 | 5.32e-03 | 55 |
GO:00109597 | Endometrium | AEH | regulation of metal ion transport | 66/2100 | 406/18723 | 1.24e-03 | 1.07e-02 | 66 |
GO:000189415 | Endometrium | EEC | tissue homeostasis | 51/2168 | 268/18723 | 2.34e-04 | 2.75e-03 | 51 |
GO:001095914 | Endometrium | EEC | regulation of metal ion transport | 70/2168 | 406/18723 | 4.12e-04 | 4.35e-03 | 70 |
GO:006024914 | Endometrium | EEC | anatomical structure homeostasis | 56/2168 | 314/18723 | 6.52e-04 | 6.35e-03 | 56 |
GO:0042220 | Liver | NAFLD | response to cocaine | 13/1882 | 55/18723 | 2.64e-03 | 2.42e-02 | 13 |
GO:00432791 | Liver | HCC | response to alkaloid | 62/7958 | 115/18723 | 8.79e-03 | 3.42e-02 | 62 |
GO:00331732 | Prostate | BPH | calcineurin-NFAT signaling cascade | 16/3107 | 43/18723 | 9.26e-04 | 5.91e-03 | 16 |
GO:00708842 | Prostate | BPH | regulation of calcineurin-NFAT signaling cascade | 13/3107 | 34/18723 | 2.06e-03 | 1.16e-02 | 13 |
GO:00480163 | Prostate | BPH | inositol phosphate-mediated signaling | 18/3107 | 55/18723 | 2.50e-03 | 1.34e-02 | 18 |
GO:01060562 | Prostate | BPH | regulation of calcineurin-mediated signaling | 13/3107 | 35/18723 | 2.79e-03 | 1.47e-02 | 13 |
GO:00977202 | Prostate | BPH | calcineurin-mediated signaling | 16/3107 | 48/18723 | 3.45e-03 | 1.77e-02 | 16 |
GO:00326232 | Prostate | BPH | interleukin-2 production | 19/3107 | 62/18723 | 4.41e-03 | 2.16e-02 | 19 |
GO:00326632 | Prostate | BPH | regulation of interleukin-2 production | 19/3107 | 62/18723 | 4.41e-03 | 2.16e-02 | 19 |
GO:006024910 | Prostate | BPH | anatomical structure homeostasis | 68/3107 | 314/18723 | 1.10e-02 | 4.53e-02 | 68 |
GO:00331731 | Prostate | Tumor | calcineurin-NFAT signaling cascade | 16/3246 | 43/18723 | 1.50e-03 | 9.27e-03 | 16 |
GO:000189416 | Prostate | Tumor | tissue homeostasis | 65/3246 | 268/18723 | 2.39e-03 | 1.35e-02 | 65 |
GO:006024915 | Prostate | Tumor | anatomical structure homeostasis | 74/3246 | 314/18723 | 2.82e-03 | 1.54e-02 | 74 |
GO:00708841 | Prostate | Tumor | regulation of calcineurin-NFAT signaling cascade | 13/3246 | 34/18723 | 3.09e-03 | 1.63e-02 | 13 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa040689 | Esophagus | ESCC | FoxO signaling pathway | 89/4205 | 131/8465 | 1.56e-05 | 7.98e-05 | 4.09e-05 | 89 |
hsa0406814 | Esophagus | ESCC | FoxO signaling pathway | 89/4205 | 131/8465 | 1.56e-05 | 7.98e-05 | 4.09e-05 | 89 |
hsa04068 | Liver | NAFLD | FoxO signaling pathway | 30/1043 | 131/8465 | 4.91e-04 | 8.05e-03 | 6.49e-03 | 30 |
hsa040681 | Liver | NAFLD | FoxO signaling pathway | 30/1043 | 131/8465 | 4.91e-04 | 8.05e-03 | 6.49e-03 | 30 |
hsa040682 | Liver | Cirrhotic | FoxO signaling pathway | 52/2530 | 131/8465 | 9.98e-03 | 3.32e-02 | 2.05e-02 | 52 |
hsa040683 | Liver | Cirrhotic | FoxO signaling pathway | 52/2530 | 131/8465 | 9.98e-03 | 3.32e-02 | 2.05e-02 | 52 |
hsa040684 | Liver | HCC | FoxO signaling pathway | 85/4020 | 131/8465 | 3.99e-05 | 2.16e-04 | 1.20e-04 | 85 |
hsa040685 | Liver | HCC | FoxO signaling pathway | 85/4020 | 131/8465 | 3.99e-05 | 2.16e-04 | 1.20e-04 | 85 |
hsa040687 | Prostate | BPH | FoxO signaling pathway | 54/1718 | 131/8465 | 3.05e-08 | 3.59e-07 | 2.22e-07 | 54 |
hsa0406812 | Prostate | BPH | FoxO signaling pathway | 54/1718 | 131/8465 | 3.05e-08 | 3.59e-07 | 2.22e-07 | 54 |
hsa0406822 | Prostate | Tumor | FoxO signaling pathway | 54/1791 | 131/8465 | 1.32e-07 | 1.51e-06 | 9.36e-07 | 54 |
hsa0406832 | Prostate | Tumor | FoxO signaling pathway | 54/1791 | 131/8465 | 1.32e-07 | 1.51e-06 | 9.36e-07 | 54 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HOMER2 | SNV | Missense_Mutation | rs372825300 | c.1000N>A | p.Asp334Asn | p.D334N | Q9NSB8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
HOMER2 | SNV | Missense_Mutation | rs752308964 | c.568N>T | p.Leu190Phe | p.L190F | Q9NSB8 | protein_coding | deleterious(0) | probably_damaging(0.938) | TCGA-AO-A03P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | PD |
HOMER2 | SNV | Missense_Mutation | c.883G>A | p.Glu295Lys | p.E295K | Q9NSB8 | protein_coding | deleterious(0) | benign(0.355) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
HOMER2 | SNV | Missense_Mutation | c.614N>A | p.Ala205Glu | p.A205E | Q9NSB8 | protein_coding | tolerated(0.06) | benign(0.001) | TCGA-E2-A14R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
HOMER2 | SNV | Missense_Mutation | c.661N>A | p.Glu221Lys | p.E221K | Q9NSB8 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-EW-A1PB-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
HOMER2 | SNV | Missense_Mutation | novel | c.1057N>A | p.Asp353Asn | p.D353N | Q9NSB8 | protein_coding | deleterious(0.03) | possibly_damaging(0.635) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
HOMER2 | SNV | Missense_Mutation | c.303N>C | p.Glu101Asp | p.E101D | Q9NSB8 | protein_coding | tolerated(0.11) | benign(0.007) | TCGA-FU-A23K-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
HOMER2 | SNV | Missense_Mutation | c.637N>G | p.Arg213Gly | p.R213G | Q9NSB8 | protein_coding | deleterious(0) | benign(0.02) | TCGA-AA-3842-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folinic | PD | |
HOMER2 | SNV | Missense_Mutation | c.808C>A | p.Leu270Ile | p.L270I | Q9NSB8 | protein_coding | deleterious(0.02) | benign(0.343) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
HOMER2 | SNV | Missense_Mutation | rs201320170 | c.136N>T | p.Arg46Trp | p.R46W | Q9NSB8 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |